COVID jabs for kids: they're safe and they work - so why is uptake so patchy?

Article Medicine, General & Internal

Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age

E. B. Walter et al.

Summary: A regimen of two 10-mu g doses of BNT162b2 administered 21 days apart was found to be safe, immunogenic, and efficacious in children aged 5 to 11 years.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

BNT162b2 Protection against the Omicron Variant in Children and Adolescents

A. M. Price et al.

Summary: In this study evaluating BNT162b2, vaccine effectiveness against hospitalization for Covid-19 in the delta-predominant period among adolescents 12 to 18 years of age was more than 90%; during the omicron period, vaccine effectiveness was 40% against hospitalization and 79% against critical illness. Vaccine effectiveness against hospitalization was 68% among children 5 to 11 years of age.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Public, Environmental & Occupational Health

Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network, 10 States, April 2021–January 2022

Nicola P. Klein et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)

Add to Collection

Article Public, Environmental & Occupational Health

Hospitalizations of Children Aged 5–11 Years with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, March 2020–February 2022

Dallas S. Shi et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)

Add to Collection

Article Medicine, General & Internal

Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5-11 years in Italy: a retrospective analysis of January-April, 2022

Chiara Sacco et al.

Summary: By April 13, 2022, less than 40% of 5-11-year-olds in Italy had been vaccinated against COVID-19 with BNT162b2 (Pfizer-BioNTech), with vaccine effectiveness in preventing SARS-CoV-2 infection and severe COVID-19 found to be lower in this age group compared to individuals aged 12 years and older. The study also noted a decrease in effectiveness against infection after completion of the current primary vaccination cycle.

LANCET (2022)

Add to Collection

Article Medicine, General & Internal

Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age

Sharon H. X. Tan et al.

Summary: This study found that the BNT162b2 vaccine reduced the risks of SARS-CoV-2 infection and Covid-19-related hospitalization among children 5 to 11 years of age during a period when the omicron variant was predominant.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Pediatrics

Long COVID symptoms in SARS-CoV-2-positive children aged 0-14 years and matched controls in Denmark (LongCOVIDKidsDK): a national, cross-sectional study

Selina Kikkenborg Berg et al.

Summary: This study investigated the prevalence of long-lasting symptoms in children aged 0-14 years infected with SARS-CoV-2, finding that the infected group had longer symptom duration and better quality of life scores related to emotional and social functioning in certain age groups.

LANCET CHILD & ADOLESCENT HEALTH (2022)

Add to Collection

Article Pediatrics

Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2

Erika Molteni et al.

Summary: Most school-aged children in the UK with SARS-CoV-2 infection are asymptomatic or experience mild illness, with longer duration and higher symptom burden observed in older children. Persistence of illness is more common in older children, but symptom burden does not increase over time and most recover within 56 days. Children who test negative for SARS-CoV-2 may also experience prolonged illness with higher symptom burden.

LANCET CHILD & ADOLESCENT HEALTH (2021)

Add to Collection

COVID jabs for kids: they're safe and they work - so why is uptake so patchy?

Related references

Export Citation

Share Paper